Cardiac light-chain deposition disease and hints at diagnosing: a case report

Abstract Background Light-chain deposition disease (LCDD) is a systemic disorder characterized by non-amyloidotic light-chain deposition in various organs with Bence-Jones type monoclonal gammopathy. Although known as monoclonal gammopathy of renal significance, it may involve interstitial tissue of various organs, and in rare cases, proceeds to organ failure. We present a case of cardiac LCDD in a patient initially suspected of dialysis-associated cardiomyopathy. Case summary A 65-year-old man with end-stage renal disease requiring haemodialysis presented with fatigue, anorexia, and shortness of breath. He had a history of recurrent congestive heart failure and Bence-Jones type monoclonal gammopathy. A cardiac biopsy performed for suspected light-chain cardiac amyloidosis was negative for diagnostic Congo-red stain, however, paraffin immunofluorescence examination for light-chain suggested diagnosis of cardiac LCDD. Discussion Cardiac LCDD may go undetected leading to heart failure due to lack of clinical awareness and insufficient pathological investigation. In heart failure cases with Bence-Jones type monoclonal gammopathy, clinicians should consider not only amyloidosis but also interstitial light-chain deposition. In addition, in patients with chronic kidney disease of unknown cause, investigation is recommended to rule out cardiac light-chain deposition disease concomitant with renal LCDD. Although LCDD is relatively rare it occasionally affects multiple organs; therefore, it would be better to describe it as a monoclonal gammopathy of clinical significance rather than one of renal significance.

[1]  O. Pfister,et al.  Nonamyloidotic light chain deposition cardiomyopathy. , 2021, European Heart Journal-Cardiovascular Imaging.

[2]  M. Copin,et al.  Paraffin Immunofluorescence Increases Light-Chain Detection in Extra-Renal Light Chain Amyloidosis and Other Light-Chain-Associated Diseases. , 2020, Archives of pathology & laboratory medicine.

[3]  S. Plein,et al.  Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review , 2016, Journal of Cardiovascular Magnetic Resonance.

[4]  N. Gokden,et al.  A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma , 2016, The American journal of case reports.

[5]  C. Kim,et al.  A Case of Cardiac Dysfunction Associated with Monoclonal Gammopathy of Undetermined Significance , 2009, Journal of Korean medical science.

[6]  F. Locatelli,et al.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  T. Masuda,et al.  Reversible restrictive cardiomyopathy due to light-chain deposition disease. , 2002, Mayo Clinic proceedings.

[8]  I. Kronzon,et al.  Infiltrative Nonamyloidotic Monoclonal Immunoglobulin Light Chain Cardiomyopathy: An Underappreciated Manifestation of Plasma Cell Dyscrasias , 2000, Cardiology.

[9]  L. Denoroy,et al.  Overrepresentation of the V kappa IV subgroup in light chain deposition disease. , 1994, Immunology letters.

[10]  M. Cogné,et al.  Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. , 1991, The Journal of clinical investigation.